Altimmune, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Altimmune, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.0K | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $20.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $426.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($68.0K) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $4.41M | Feb 28, 2023 |
| FY2011 | Dec 31, 2011 | $24.27M | Mar 8, 2012 |
| FY2011 | Dec 31, 2010 | $20.99M | Mar 8, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $4.41M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $8.19M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $5.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $10.33M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $10.74M | Apr 1, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $10.74M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $3.24M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($88.09M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($95.06M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($88.45M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($84.71M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($97.09M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($49.04M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($20.52M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($39.17M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($46.43M) | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $77.80M | Mar 14, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($94.49M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($103.17M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($95.93M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($87.74M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($96.91M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($54.80M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($21.46M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($42.83M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($52.05M) | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | ($5.51M) | Mar 14, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $279.93M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $139.31M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $210.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $206.93M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $218.87M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $245.12M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $54.06M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $54.75M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $63.03M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $38.40M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.04M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $15.80M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $16.54M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $21.64M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $19.73M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $19.24M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $8.54M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $6.44M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $14.35M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.19M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $224.89M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $123.51M | Mar 6, 2026 |
| FY2025 | Dec 31, 2023 | $194.10M | Mar 6, 2026 |
| FY2024 | Dec 31, 2022 | $185.29M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $199.14M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $225.88M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $45.52M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $48.31M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $39.40M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $32.21M | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 15, 2022 |
| FY2016 | Dec 31, 2016 | 1 | Mar 14, 2017 |
| FY2016 | Sep 30, 2016 | 1 | Mar 14, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Mar 14, 2017 |
| FY2016 | Mar 31, 2016 | 0 | Mar 14, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 15, 2022 |
| FY2016 | Dec 31, 2016 | 1 | Mar 14, 2017 |
| FY2016 | Sep 30, 2016 | 1 | Mar 14, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Mar 14, 2017 |
| FY2016 | Mar 31, 2016 | 0 | Mar 14, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.76M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $36.93M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $135.12M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $111.10M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $190.30M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $115.92M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $8.96M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $33.72M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.77M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.88M | Apr 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.29M | Mar 6, 2026 |
| FY2018 | Dec 31, 2018 | 500,000 | Apr 1, 2019 |
| FY2018 | Dec 31, 2018 | $572.8K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 500,000 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $599.9K | Apr 1, 2019 |